IntegraGen, a company focused on the development and commercialisation of genetic tests for complex diseases, has announced that DSM Venturing has invested euro2M in the company
In addition, it has entered into a collaborative R+D partnership with the DSM personalised nutrition group for the development of molecular diagnostic products for personalised healthcare.
IntegraGen is focused on the development of diagnostic and prognostic genetic tests for a range of complex diseases using its proprietary technology platform for gene identification (Genome HIP).
Under the terms of the agreement with DSM, the company will receive upfront fees, license fees and funding for research and development.
In addition, IntegraGen will be eligible for royalties upon commercialisation.
Each company will retain rights to the intellectual property portfolio developed under the collaboration in their areas of focus, being diagnostics and medicines for IntegraGen and nutrition for DSM.
Jan Mous, president and CEO of IntegraGen, said: "The DSM collaboration enhances our position in the personalized medicine market, promising to further expand our patent portfolio and commercialised products in the areas of obesity and metabolic disorders".
"The DSM relationship is a testimonial to the value of IntegraGen's intellectual property and capabilities for identifying genes of interest to IntegraGen and partners in the diagnostics and personalised healthcare markets".
